The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer.
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
Silvia Damian
Employment - Biofarma Group (I)
Leadership - Biofarma Group (I)
Research Funding - Amgen (Inst); Incyte (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Ilaria Colombo
Employment - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE; GlaxoSmithKline (Inst); Incyte (Inst); MSD Oncology (Inst)
Speakers' Bureau - Abbvie (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst)
Research Funding - Incyte (Inst); Merck KGaA (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst); Orion Clinical (Inst); Tolremo (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Edward Wang
No Relationships to Disclose
 
Maikel van der Velden
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Elisabeth Richards
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Michelle Kinder
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Qingyang Liu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Rebecca Kristeleit
Honoraria - Abbvie; Abbvie; AstraZeneca; Basilea Pharmaceutical; Celcuity; Clovis Oncology; Eisai; Genmab; GlaxoSmithKline; Incyte; Leucid Bio; Merck Sharp & Dohme; MSD Oncology; Pharma&; Regeneron; Roche/Genentech; Shattuck Labs; Tesaro
Consulting or Advisory Role - Basilea; Clovis Oncology
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; MSD Oncology